Objective To investigate the effect of doxofylline combined with compound ipratropium bromide on exercise tolerance and serum inflammatory mediator levels in patients with acute exacerbation of chronic obstructive pulmonary disease(COPD).Meth-ods A total of 78 patients with acute exacerbation of COPD were admitted to the hospital from July 2021 to March 2023.They were divided into observation group(39 cases)and control group(39 cases)using the random number table.The control group was trea-ted with compound ipratropium bromide,while the observation group was treated with doxofylline combined with compound ipratropium bromide.Comparison between groups was made on clinical efficacy,pulmonary function,serum inflammatory factor levels,exercise tolerance,and the incidence of adverse reactions.Results Comparison between groups found that the total clinical response rate in the observation group was higher(P<0.05);after treatment,compared with the control group,forced expiratory volume in 1s(FEV1),forced vital capacity(FCV),peak expiratory flow(PEF)and FEV1/FCV in observation group were significantly higher.The levels of high-sensitivity C-reactive protein(hs-CRP),procalcitonin(PCT)and tumor necrosis factor-α(TNF-α)were sig-nificantly lower.The exercise tolerance score of observation group was significantly higher.After treatment,partial pressure of oxygen(PaO2)and arterial oxygen saturation(SaO2)in observation group were significantly higher,while partial pressure of nitrogen diox-ide(PaCO2)was significantly lower.There was statistical significance in the above indexes(P<0.05),but there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion For patients with acute exacerbation of COPD,the combined treatment of doxofylline and compound ipratropium bromide can achieve better clinical effect than compound ipratropium bromide alone.It can effectively promote pulmonary function recovery,reduce inflammatory reactions,improve arterial blood gas and enhance exercise tolerance without increasing safety risk of clinical medication.
NETL
NSTL
万方数据
